ZYT1

ZYT1 is a novel small molecule drug developed as a selective thyroid hormone receptor beta (THR-β) agonist. It was designed to act as an anti-dyslipidemic agent for the treatment of dyslipidemia and related lipid metabolism disorders. The mechanism of action involves selective activation of the thyroid hormone receptor beta, which plays a key role in regulating cholesterol and triglyceride metabolism. Preclinical studies demonstrated that ZYT1 could lower LDL-cholesterol and triglycerides with efficacy comparable to statins, and it showed additive effects when combined with statin therapy. The drug was intended for oral administration and underwent Phase 1 clinical trials to assess safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy volunteers. Despite initial promise as an alternative or adjunct to statins for managing dyslipidemia, development was discontinued after Phase 1 trials[2][3][5][7].